Evidence map›Paper›PMID 34440745›Full record

ArticleCells2021

Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.

Phuong Doan, Phung Nguyen, Akshaya Murugesan, Nuno R Candeias, Olli Yli-Harja, Meenakshisundaram Kandhavelu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Intrinsic and Microenvironmental Drivers of Glioblastoma Invasion.International journal of molecular sciences · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Phuong DoanMolecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University, P.O. Box 553, 33101 Tampere, Finland.
Phung NguyenMolecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University, P.O. Box 553, 33101 Tampere, Finland.
Akshaya MurugesanMolecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University, P.O. Box 553, 33101 Tampere, Finland.
Nuno R CandeiasFaculty of Engineering and Natural Sciences, Tampere University, P.O. Box 553, 33101 Tampere, Finland.ORCID 0000-0003-2414-9064
Olli Yli-HarjaBioMediTech Institute and Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland.
Meenakshisundaram KandhaveluMolecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University, P.O. Box 553, 33101 Tampere, Finland.
Tampere University · FI

Funding

Academy of Finland 29720
6 · The paper itself

Abstract

Drug resistance and tumor heterogeneity limits the therapeutic efficacy in treating glioblastoma, an aggressive infiltrative type of brain tumor. GBM cells develops resistance against chemotherapeutic agent, temozolomide (TMZ), which leads to the failure in treatment strategies. This enduring challenge of GBM drug resistance could be rational by combinatorial targeted therapy. Here, we evaluated the combinatorial effect of phenolic compound (2-(3,4-dihydroquinolin-1(2H)-yl)(

Indexed as

AnimalsAntineoplastic AgentsApoptosisBrain NeoplasmsCalciumCaspase 3Cell Line, TumorCell Membrane PermeabilityCell MovementDrug SynergismGlioblastomaHumansMiceMice, Inbred BALB CPhenolsProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsCalciumCaspase 3GPR17 protein, humanPhenolsProto-Oncogene Proteins c-bcl-2Reactive Oxygen SpeciesReceptors, G-Protein-CoupledTemozolomidealkylaminophenolcell cycle arrestglioblastomaGPR17 agonistintrinsic apoptotic pathwaymesenchymal GBMsynergy

Identifiers

PMID34440745
PMCPMC8393831
OpenAlexW3190491649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.